ERBB2 and breast carcinoma: NRG Oncology/NSABP B‐47 is a phase III, multicenter, randomized adjuvant therapy trial designed to evaluate the addition of trastuzumab to adjuvant chemotherapy in patients with HER2-low breast cancer.